MedPath

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Phase 2
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: Placebo
Registration Number
NCT05061446
Lead Sponsor
Pfizer
Brief Summary

The purpose of this Japan-only study is to assess the safety and efficacy of etrasimod at 2 doses in Japanese subjects with moderately to severely active ulcerative colitis (UC) when administered for 12 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria
  • Japanese ancestry
  • Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
  • Having active UC confirmed by endoscopy
  • Moderately to severely active UC
Exclusion Criteria
  • Severe extensive colitis
  • Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence, history of a fistula consistent with CD
  • Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Etrasimod Dose 1Etrasimod-
PlaceboPlacebo-
Etrasimod Dose 2Etrasimod-
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Who Achieved Clinical Remission at Week 12Week 12

Clinical remission:Participants with stool frequency (SF)subscore=0(or of 1 with greater than or equal to(\>=)1 point decrease from baseline,rectal bleeding(RB)subscore=0 and endoscopic score(ES)less than or equal to(\<)=1(excluding friability).SF subscore:number of stools in 24-hours relative to normal number of stools for that participant in same period,score ranged from 0(normal number of stools) to 3(5 or more stools than normal),higher scores=more severity.RB subscore:most severe amount of blood passed per rectum in 24-hours,score ranged from 0(no blood seen)to 3(blood alone passes),higher scores=more severity.ES:reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy,score ranged from 0(normal or inactive disease) to 3(severe disease \[spontaneous bleeding,ulceration\]),higher scores=more severity.Modified Mayo score:measure disease activity for UC,score:0(normal) to 9(maximum severity),comprised subscores for SF,RB,ES.higher score=more severe disease activity.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Who Achieved Endoscopic Improvement at Week 12Week 12

Endoscopic improvement was defined as ES \<= 1 (excluding friability). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. Modified Mayo score (MMS): measure disease activity for UC, score: 0 (normal) to 9 (maximum severity),and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity.

Percentage of Participants Who Achieved Symptomatic Remission at Week 12Week 12

Symptomatic remission was defined as SF sub score = 0 (or = 1 with a \>= 1 point decrease from baseline) and RB sub score = 0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. MMS: measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity.

Percentage of Participants Who Achieved Mucosal Healing at Week 12Week 12

Mucosal healing was defined as ES \<= 1 (excluding friability) with histologic remission defined as a Geboes index score \< 2.0). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease. Modified Mayo score (MMS): measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), comprised subscores for SF, RB, ES. Higher score = more severe disease activity.

Percentage of Participants Who Achieved Clinical Response at Week 12Week 12

Clinical response was defined as a \>= 2-point and \>= 30 percentage (%) decrease from baseline in MMS, and a \>= 1-point decrease from baseline in RB subscore or an absolute RB subscore \<= 1. MMS: measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity.

Percentage of Participants Who Achieved Endoscopic Normalization at Week 12Week 12

Endoscopic normalization was defined as ES= 0. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. MMS: measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity.

Trial Locations

Locations (79)

NHO Hirosaki General Medical Center

🇯🇵

Hirosaki-shi, Aomori-ken, Japan

Our Lady of the Snow St. Mary's Hospital

🇯🇵

Kurume, Fukuoka, Japan

Kudo Internist Heart Clinic

🇯🇵

Morioka-shi, Iwate-ken, Japan

Hamamatsu Medical Centre

🇯🇵

Hamamatsu-shi, Shizuoka-ken, Japan

Toyohashi Municipal Hospital

🇯🇵

Toyohashi-shi, Aichi- KEN, Japan

Aichi Medical University Hospital

🇯🇵

Nagakute, Aichi, Japan

Kojunkai Daido Clinic

🇯🇵

Nagoya-shi, Aichi, Japan

Nagoya City University Hospital

🇯🇵

Nagoya-shi, Aichi, Japan

Fujita Health University Hospital

🇯🇵

Toyoake-City, Aichi, Japan

Kojunkai Daido Hospital

🇯🇵

Nagoya-shi, Aixhi-ken, Japan

Hirosaki University Hospital(OCT/PFT/DLCO)

🇯🇵

Hirosaki-shi, Aomori KEN, Japan

Hirosaki University Hospital

🇯🇵

Hirosaki-shi, Aomori KEN, Japan

Tsujinaka Hospital Kashiwanoha

🇯🇵

Kashiwa-shi, Chiba, Japan

Ishii Eye Clinic

🇯🇵

Nagareyama-shi, Chiba, Japan

Toho University Sakura Medical Center

🇯🇵

Sakura, Chiba, Japan

Saiseikai Matsuyama Hospital

🇯🇵

Matsuyama-shi, Ehime, Japan

Ehime University Hospital

🇯🇵

Toon-shi, Ehime, Japan

Fukuoka University Hospital

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Kokura Memorial Hospital

🇯🇵

Kutakyushu-shi, Fukuoka, Japan

Kitakyushu Municipal Medical Center

🇯🇵

Kitakyushu-shi, Fukuoka, Japan

Koyanose Eye Clinic

🇯🇵

Kitakyushu-shi, Fukuoka, Japan

Japan Community Health Care Organization Kyushu Hospital

🇯🇵

Kitakyushu, Fukuoka, Japan

Kurume University Hospital

🇯🇵

Kurume-shi, Fukuoka, Japan

Fukuoka Shinmizumaki Hospital

🇯🇵

Onga-gun, Fukuoka, Japan

Gifu University Hospital

🇯🇵

Gifu-shi, Gifu-ken, Japan

SUBARU Health Insurance Society Ota Memorial Hospital

🇯🇵

Ota-shi, Gunma, Japan

Nakayama EYE Clinic

🇯🇵

Fukuyama-shi, Hiroshima, Japan

NHO Fukuyama Medical Center

🇯🇵

Fukuyama-shi, Hiroshima, Japan

Hiroshima University Hospital

🇯🇵

Hiroshima-shi, Hiroshima, Japan

Asahikawa City Hospital

🇯🇵

Asahikawa-shi, Hokkaido, Japan

Tokushukai Sapporo Tokushukai Hospital

🇯🇵

Sapporo-shi, Hokkaido, Japan

Sapporo-Kosei General Hospital

🇯🇵

Sapporo-shi, Hokkaido, Japan

NHO Mito Medical Center

🇯🇵

Higashiibaraki-gun, Ibaraki, Japan

Yuai Memorial Hospital

🇯🇵

Koga-shi, Ibaraki, Japan

Ibaraki Seinan Medical Center Hospital

🇯🇵

Sashima-gun, Ibaraki, Japan

Matsumoto Eye Clinic

🇯🇵

Toride-shi, Ibaraki, Japan

Tsuchiura Kyodo General Hospital

🇯🇵

Tsuchiura-shi, Ibaraki, Japan

NHO Kanazawa Medical Center

🇯🇵

Kanazawa-shi, Ishikawa, Japan

Iwate Medical University Uchimaru Medical Center

🇯🇵

Morioka-shi, Iwate, Japan

Takamatsu Red Cross Hospital

🇯🇵

Takamatsu-shi, Kagawa, Japan

JA- Kagoshima Koseiren Hospital (PET/DLCO)

🇯🇵

Kagoshima-shi, Kagoshima, Japan

Clinical Pathology Laboratory (Diagnostick center)

🇯🇵

Kagoshima-shi, Kagoshima, Japan

Sameshima Eye Clinic (OCT)

🇯🇵

Kagoshima-shi, Kagoshima, Japan

Sameshima Hospital

🇯🇵

Kagoshima-shi, Kagoshima, Japan

Sagamihara Kyodo Hospital

🇯🇵

Sagamihara, Kanagawa, Japan

Social Welfare Organization Imperial Gift Foundation,Inc.Saiseikai Yokohamashi Nanbu Hospital

🇯🇵

Yokohama-shi, Kanagawa, Japan

NHO Yokohama Medical Center

🇯🇵

Yokohama-shi, Kanagawa, Japan

Japanese Red Cross Kumamoto Hospital

🇯🇵

Kumamoto-shi, Kumamoto, Japan

University Hospital Kyoto Prefectural University of Medicine

🇯🇵

Kyoto-shi, Kyoto, Japan

National Hospital Organization Kyoto Medical Center

🇯🇵

Kyoto-shi, Kyoto, Japan

Hinaga Nishi Ophthalmology Clinic

🇯🇵

Yokkaichi- Shi, Mie-ken, Japan

Mie Prefectural General Medical Center

🇯🇵

Yokkaichi-shi, Mie-ken, Japan

Mie University Hospital

🇯🇵

Tsu-shi, MIE, Japan

JOHAS Tohoku Rosai Hospital

🇯🇵

Sendai-shi, Miyagi, Japan

Tohoku University Hospital

🇯🇵

Sendai, Miyagi, Japan

Nagaoka Red Cross Hospital

🇯🇵

Nagaoka-shi, Niigata, Japan

Kansai Medical University Hospital

🇯🇵

Hirakata-shi, Osaka, Japan

Medical Corporation Tokushukai Kishiwada Tokushukai Hospital

🇯🇵

Kishiwada-shi, Osaka, Japan

Osaka City University Hospital

🇯🇵

Osaka-shi, Osaka, Japan

Japan Community Health care Organization Osaka Hospital

🇯🇵

Osaka-shi, Osaka, Japan

Osaka Medical and Pharmaceutical University Hospital

🇯🇵

Takatsuki-City, Osaka, Japan

Saga University Hospital

🇯🇵

Saga-shi, Saga, Japan

Japan Community Health care Organization Saitama Medical Center

🇯🇵

Saitama-shi, Saitama-ken, Japan

Saitama Medical University Hospital

🇯🇵

Iruma-gun, Saitama, Japan

Shiga University of Medical Science Hospital

🇯🇵

Otsu, Shiga, Japan

Hamamatsu University Hospital

🇯🇵

Hamamatsu-shi, Shizuoka, Japan

Matsuda Hospital

🇯🇵

Hamamatsu, Shizuoka, Japan

Tokyo Medical and Dental University Hospital

🇯🇵

Bunkyo-ku, Tokyo, Japan

Tokai University Hachioji Hospital

🇯🇵

Hachioji, Tokyo, Japan

Showa General Hospital

🇯🇵

Kodaira-shi, Tokyo, Japan

Kitasato University Kitasato Institute Hospital

🇯🇵

Minato-ku, Tokyo, Japan

JCHO Tokyo Yamate Medical Center

🇯🇵

Shinjuku-ku, Tokyo, Japan

Wakayama Medical University Hospital

🇯🇵

Wakayama-shi, Wakayama, Japan

Yamanashi Prefectural Central Hospital

🇯🇵

Kofu-shi, Yamanashi, Japan

Fukushima Medical University Hospital

🇯🇵

Fukushima, Japan

Kagoshima University Hospital

🇯🇵

Kagoshima, Japan

NHO Osaka National Hospital

🇯🇵

Osaka, Japan

Osaka National Hospital Institutional Review Board

🇯🇵

Osaka, Japan

Teikyo University Hospital

🇯🇵

Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath